未登录
分享
收藏AIR - an open-label, 36-week, clinical trial of buloxibutid - investigating the disease modifying potential of a novel angiotensin II type 2 receptor agonist in IPF
Ganslandt, Cecilia; Molyneaux, Philip; Devaraj, Anand; Lindmark, Bertil; Raud, Johan; Tornling, Goran; Bengtsson, Thomas; Maher, Toby M.
分享
收藏
分享
收藏
分享
收藏An open-label, pharmacodynamic trial investigating vascular effects of the angiotensin II type 2 receptor (AT2R) agonist (ATRAG) C21
Ganslandt, Cecilia; Rein-Hedin, Erik; Sjoberg, Folke; Tornling, Goran; Bengtsson, Thomas; Overbeck, Kamilla; Rosendahl, Elin; Batta, Rohit; Bjerring, Barbara; Raud, Johan; Dalsgaard, Carl-Johan
分享
收藏Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial
Tornling, Goran; Batta, Rohit; Porter, Joanna C.; Williams, Bryan; Bengtsson, Thomas; Parmar, Kartikeya; Kashiva, Reema; Hallberg, Anders; Cohrt, Anne Katrine; Westergaard, Kate; Dalsgaard, Carl-Johan; Raud, Johan
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏